Fertility benefits have grown into one of the more competitive categories in employee benefits over the past several years, with companies advertising egg freezing coverage, IVF cycles, and fertility preservation as a recruiting differentiator, particularly for younger workforces. Almost all of that early benefit design was built around women, reflecting the historical assumption, still common among both employers and patients, that fertility is primarily a woman's medical issue. Male factor contributes to roughly half of infertility cases, and yet coverage for the diagnostic and treatment steps specific to men, semen analysis, urological evaluation, and in some cases surgical intervention for treatable causes, has lagged far behind.
That gap is starting to close, driven by a combination of clinical evidence about male factor's real prevalence, growing awareness among benefits consultants that a fertility benefit missing half the couple is an incomplete product, and the practical reality that many fertility treatment cycles fail or need to be repeated for reasons that trace back to an undiagnosed male factor issue that a female-only benefit structure never screened for.
Why male factor got overlooked for so long
Part of the historical gap traces to how fertility clinics themselves were structured, with reproductive endocrinology built as a subspecialty of obstetrics and gynecology, meaning the default clinical pathway for a couple struggling to conceive routes naturally toward evaluating the woman first. Urologists with fertility subspecialty training exist but are a much smaller and less consistently integrated part of the standard fertility workup in many practices, meaning a male partner's evaluation, when it happens at all, often comes later in the process rather than at the outset alongside the woman's testing.
The consequence has been a pattern where couples undergo multiple rounds of expensive female-focused fertility treatment before a male factor cause is identified, sometimes one that could have been treated more simply or cheaply, such as a varicocele, if caught at the start of the workup rather than after several unsuccessful cycles. Benefit designs that build simultaneous evaluation of both partners into the standard fertility benefit pathway, rather than treating the male evaluation as an afterthought triggered only after female treatment fails, are addressing this sequencing problem directly.
What updated benefit design looks like
Employers and benefit administrators expanding coverage in this area have generally started with the lowest-friction addition: covering or subsidizing a semen analysis as a standard part of the initial fertility benefit intake for any employee reporting difficulty conceiving, rather than requiring a separate referral process. Some have gone further, covering urological consultation and treatment for identified, correctable causes of male infertility, and a smaller number have begun covering fertility preservation options for men undergoing treatments that can affect fertility, extending a benefit that had previously been offered almost exclusively to women facing similar treatments.
The at-home and telehealth male fertility testing companies that have grown over the past two years have played a direct role in making this expansion practical for benefit administrators, since a simple, low-cost, high-volume screening step is far easier to fold into a benefit plan than requiring every employee to book a specialist urology consultation as the entry point. That lower barrier has made it administratively realistic for benefits teams to include male testing as a default rather than an opt-in add-on.
The clinical case for going first, not last
Fertility specialists have long argued that evaluating both partners simultaneously at the start of a fertility workup, rather than sequentially, produces better outcomes and avoids wasted treatment cycles. A benefit design that reflects that clinical sequencing, rather than the historical default of evaluating the woman first and the man only if initial treatment fails, is a genuine improvement in care quality, not simply an equity gesture. Couples who receive a full picture of both partners' fertility factors from the outset can make better informed decisions about which treatment path, timed intercourse, intrauterine insemination, or IVF, is actually appropriate for their specific situation, rather than defaulting to an escalating series of treatments aimed at a diagnosis that was never fully established.
Key Signals
The expansion of employer fertility benefits to include structured male evaluation reflects a correction of a genuine clinical sequencing error, not merely a benefits parity gesture, since evaluating both partners from the outset produces better treatment decisions and fewer wasted cycles. The growth of low-cost, high-volume at-home male fertility testing has been a direct practical enabler of this benefit expansion, since it gave administrators an accessible entry point that did not require every employee to book a specialist consultation. Benefit plans that still treat male evaluation as a fallback step, triggered only after female-focused treatment has failed, are preserving exactly the sequencing problem that has led to costly, avoidable repeat treatment cycles for years. As more employers add this coverage, fertility clinics that have built efficient, low-friction male evaluation pathways alongside their existing female-focused services are best positioned to capture the resulting referral volume.
